LY-503430

Source: Wikipedia, the free encyclopedia.
(Redirected from
LY-503,430
)
LY-503430
Clinical data
Other namesLY-503430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
Routes of
administration		Oral
Legal status
Legal status
Identifiers
  • 4'-{(1S)-1-fluoro-2-[(isopropylsulfonyl)amino]-1-methylethyl}-N-methylbiphenyl-4-carboxamide
JSmol)
  • CC(C)S(=O)(=O)NCC(F)(C)c(cc2)ccc2-c(cc1)ccc1C(=O)NC
  • InChI=1S/C20H25FN2O3S/c1-14(2)27(25,26)23-13-20(3,21)18-11-9-16(10-12-18)15-5-7-17(8-6-15)19(24)22-4/h5-12,14,23H,13H2,1-4H3,(H,22,24)/t20-/m0/s1 ☒N
  • Key:MFJKNXILEXBWNQ-FQEVSTJZSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

LY-503430 is an

positive allosteric modulator developed by Eli Lilly.[1]

LY-503430 produces both

BDNF in the brain, particularly in the substantia nigra, hippocampus, and striatum.[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson's disease, although it has also been proposed to be useful in the treatment of Alzheimer's disease, depression, and schizophrenia.[4][5]

See also

References

  1. PMID 15867954
    .
  2. S2CID 86751458
    .
  3. S2CID 11732324
    .
  4. PMID 15180479
    .
  5. PMID 17504104
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=LY-503430&oldid=1191990934"